Overview
- Patients lost up to 12.3% of body weight versus placebo at week 28 in the ongoing phase 2 trial, with 10.5% when including all randomized participants.
- Participants received weekly injections for 12 weeks before switching to once-monthly dosing, and Pfizer reported no early plateau as the study runs to week 64.
- Modeling from the company projects about 16% weight loss at week 28 with a higher monthly dose to be used in late-stage testing.
- Safety findings were consistent with the GLP-1 class, with mostly mild to moderate gastrointestinal effects and no new safety signals; five discontinuations occurred during each dosing phase.
- The ultra-long-acting GLP-1, acquired through Metsera, will move forward with selected low and medium monthly maintenance doses as Pfizer targets a market led by Lilly and Novo Nordisk’s injectables and Novo’s new daily pill.